Menu
Kent-Athlone Pharma Group, a rapidly growing specialty European pharmaceuticals company, is pleased to announce the appointment of Olga Lund as Chief Financial Officer (CFO)
Olga brings over 20 years of experience in the pharmaceuticals industry, following an early career in insurance and banking in the City of London. A qualified accountant, she has held senior finance roles across both publicly listed and private equity-backed pharmaceutical companies, where she has supported R&D programs, product launches, international expansion, and strategic portfolio acquisitions.
A true international finance leader, Olga has successfully led multiple cross-border transactions across Europe and the MENA region and played a key role in establishing commercial operations throughout Northern Europe. In 2021, she co-led the carve-out of a European business to found CNX Therapeutics, where she most recently served as CFO. During her tenure, she oversaw a successful debt refinancing and led several major asset and corporate acquisitions.
Olga’s strategic insight and financial leadership will play a key role in driving Kent-Athlone Pharma Group’s continued growth and innovation.
Important notice: This information on Kent Pharma’s products/services is intended for UK healthcare professionals only.
By proceeding with accessing the product list, you are confirming that you are a UK healthcare professional, and that you wish to access promotional information regarding our Over-Labelling products and services, which is presented if you choose to click through to the next stage.
